Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Peking University
Sponsor:
Information provided by (Responsible Party):
Jun Zhu, Peking University
ClinicalTrials.gov Identifier:
NCT01765231
First received: January 9, 2013
Last updated: January 8, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)